Inter-tissue communication in cancer cachexia

[1]  D. Coletti.  Chemotherapy-induced muscle wasting: an update , 2018, European journal of translational myology.

[2]  W. Jin,et al.  Role of brown adipose tissue in metabolic syndrome, aging, and cancer cachexia , 2018, Frontiers of Medicine.

[3]  T. Borner,et al.  Brainstem GLP-1 signalling contributes to cancer anorexia-cachexia syndrome in the rat , 2018, Neuropharmacology.

[4]  Yanfeng Lin,et al.  Acylated and unacylated ghrelin inhibit apoptosis in myoblasts cocultured with colon carcinoma cells. , 2018, Oncology reports.

[5]  N. Girard,et al.  Bone, muscle, and metabolic parameters predict survival in patients with synchronous bone metastases from lung cancers. , 2018, Bone.

[6]  N. Delzenne,et al.  Gut microbiota in 2017: Contribution of gut microbiota–host cooperation to drug efficacy , 2018, Nature Reviews Gastroenterology & Hepatology.

[7]  Lei Shen,et al.  Interleukin-6 induces fat loss in cancer cachexia by promoting white adipose tissue lipolysis and browning , 2018, Lipids in Health and Disease.

[8]  S. Reiken,et al.  Osteolytic Breast Cancer Causes Skeletal Muscle Weakness in an Immunocompetent Syngeneic Mouse Model , 2017, Front. Endocrinol..

[9]  T. Tsuji,et al.  Anamorelin (ONO‐7643) for the treatment of patients with non–small cell lung cancer and cachexia: Results from a randomized, double‐blind, placebo‐controlled, multicenter study of Japanese patients (ONO‐7643‐04) , 2017, Cancer.

[10]  G. Meissner.  The structural basis of ryanodine receptor ion channel function , 2017, The Journal of general physiology.

[11]  E. D. Del Fabbro,et al.  Practical approaches to managing cancer patients with weight loss , 2017, Current opinion in supportive and palliative care.

[12]  V. W. Tsai,et al.  Targeting Obesity and Cachexia: Identification of the GFRAL Receptor-MIC-1/GDF15 Pathway. , 2017, Trends in molecular medicine.

[13]  M. Jeschke,et al.  Taming the Flames: Targeting White Adipose Tissue Browning in Hypermetabolic Conditions , 2017, Endocrine reviews.

[14]  Jan Dudek.  Role of Cardiolipin in Mitochondrial Signaling Pathways , 2017, Front. Cell Dev. Biol..

[15]  R. Witkamp,et al.  The role of hypothalamic inflammation, the hypothalamic–pituitary–adrenal axis and serotonin in the cancer anorexia–cachexia syndrome , 2017, Current opinion in clinical nutrition and metabolic care.

[16]  Xianliang Zeng,et al.  Acylated and unacylated ghrelin inhibit atrophy in myotubes co-cultured with colon carcinoma cells , 2017, Oncotarget.

[17]  L. Oyama,et al.  Lipases and lipid droplet-associated protein expression in subcutaneous white adipose tissue of cachectic patients with cancer , 2017, Lipids in Health and Disease.

[18]  F. López‐Soriano,et al.  Novel targeted therapies for cancer cachexia. , 2017, The Biochemical journal.

[19]  Jose M Garcia,et al.  Anamorelin hydrochloride in the treatment of cancer anorexia–cachexia syndrome: design, development, and potential place in therapy , 2017, Drug design, development and therapy.

[20]  W. Doehner,et al.  Cardiac muscle wasting in individuals with cancer cachexia , 2017, ESC heart failure.

[21]  T. Zimmers,et al.  Exogenous GDF11 induces cardiac and skeletal muscle dysfunction and wasting , 2017, Basic Research in Cardiology.

[22]  R. Cunha,et al.  Central Ghrelin Resistance Permits the Overconsolidation of Fear Memory , 2017, Biological Psychiatry.

[23]  J. M. Argiles.  The 2015 ESPEN Sir David Cuthbertson lecture: Inflammation as the driving force of muscle wasting in cancer. , 2017, Clinical nutrition.

[24]  W. Raphael,et al.  Adipose tissue lipolysis and remodeling during the transition period of dairy cows , 2017, Journal of Animal Science and Biotechnology.

[25]  B. Laird,et al.  Prognostic Tools in Patients With Advanced Cancer: A Systematic Review. , 2017, Journal of pain and symptom management.

[26]  Yassine Belloum,et al.  Cancer-induced cardiac cachexia: Pathogenesis and impact of physical activity (Review). , 2017, Oncology reports.

[27]  Xiaoyong Yang,et al.  Inter-organ regulation of adipose tissue browning , 2017, Cellular and Molecular Life Sciences.

[28]  J. Mehta,et al.  Role of Inflammation in Heart Failure , 2017, Current Atherosclerosis Reports.

[29]  A. Hichami,et al.  Alteration in Taste Perception in Cancer: Causes and Strategies of Treatment , 2017, Front. Physiol..

[30]  K. Yanagihara,et al.  Development of ghrelin resistance in a cancer cachexia rat model using human gastric cancer-derived 85As2 cells and the palliative effects of the Kampo medicine rikkunshito on the model , 2017, PloS one.

[31]  F. Celi,et al.  The role of adipose tissue in cancer-associated cachexia , 2017, Experimental biology and medicine.

[32]  M. Pero-Cebollero,et al.  Validation of the CAchexia SCOre (CASCO). Staging Cancer Patients: The Use of miniCASCO as a Simplified Tool , 2017, Front. Physiol..

[33]  T. Guise,et al.  The Role of TGFβ in Bone-Muscle Crosstalk , 2017, Current Osteoporosis Reports.

[34]  W. Aoi,et al.  Molecular mechanism of sarcopenia and cachexia: recent research advances , 2017, Pflügers Archiv - European Journal of Physiology.

[35]  T. Zimmers,et al.  Differential Bone Loss in Mouse Models of Colon Cancer Cachexia , 2017, Frontiers in physiology.

[36]  Yu Bai,et al.  Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis , 2017, Supportive Care in Cancer.

[37]  J. Steinacker,et al.  IL-4 mRNA Is Downregulated in the Liver of Pancreatic Cancer Patients Suffering from Cachexia , 2017, Nutrition and Cancer.

[38]  A. Farcomeni,et al.  Cancer anorexia: hypothalamic activity and its association with inflammation and appetite‐regulating peptides in lung cancer , 2016, Journal of cachexia, sarcopenia and muscle.

[39]  S. Verschueren,et al.  Muscle-bone interactions: From experimental models to the clinic? A critical update , 2016, Molecular and Cellular Endocrinology.

[40]  V. Baracos,et al.  Physiological and functional failure in chronic obstructive pulmonary disease, congestive heart failure and cancer: a debilitating intersection of sarcopenia, cachexia and breathlessness , 2016, Current opinion in supportive and palliative care.

[41]  P. Arner,et al.  An AMP-activated protein kinase–stabilizing peptide ameliorates adipose tissue wasting in cancer cachexia in mice , 2016, Nature Medicine.

[42]  M. Sandri.  Protein breakdown in cancer cachexia. , 2016, Seminars in cell & developmental biology.

[43]  D. Marks,et al.  The central role of hypothalamic inflammation in the acute illness response and cachexia. , 2016, Seminars in cell & developmental biology.

[44]  R. Witkamp,et al.  Increased hypothalamic serotonin turnover in inflammation-induced anorexia , 2016, BMC Neuroscience.

[45]  C. Blanchette,et al.  Cachexia among US cancer patients , 2016, Journal of medical economics.

[46]  E. Marzetti,et al.  Skeletal muscle regeneration in cancer cachexia , 2016, Clinical and experimental pharmacology & physiology.

[47]  N. Macdonald,et al.  Identification of neutrophil-derived proteases and angiotensin II as biomarkers of cancer cachexia , 2016, British Journal of Cancer.

[48]  D. Walsh,et al.  C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review , 2015, PloS one.

[49]  I. Martínez,et al.  Synbiotic approach restores intestinal homeostasis and prolongs survival in leukaemic mice with cachexia , 2015, The ISME Journal.

[50]  G. Hatch,et al.  Regulation of hepatic cardiolipin metabolism by TNFα: Implication in cancer cachexia. , 2015, Biochimica et biophysica acta.

[51]  R. Talukdar,et al.  Role of the normal gut microbiota. , 2015, World journal of gastroenterology.

[52]  G. Püschel,et al.  NF-κBp65 and Expression of Its Pro-Inflammatory Target Genes Are Upregulated in the Subcutaneous Adipose Tissue of Cachectic Cancer Patients , 2015, Nutrients.

[53]  Richard Nicoletti,et al.  Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients , 2015, Journal of cachexia, sarcopenia and muscle.

[54]  S. Basu.  Hypothesizing association between cancer cachexia and Fluorodeoxyglucose-positron emission tomography documented brown adipose tissue hypermetabolism in cancer patients with an illustration in grossly emaciated cachectic patient in hot Indian summer climate: Will beta blockers find use in the manage , 2015, Indian journal of cancer.

[55]  H. Kiyonari,et al.  Atrial natriuretic peptide prevents cancer metastasis through vascular endothelial cells , 2015, Proceedings of the National Academy of Sciences.

[56]  R. Witkamp,et al.  Differences in food intake of tumour-bearing cachectic mice are associated with hypothalamic serotonin signalling , 2015, Journal of cachexia, sarcopenia and muscle.

[57]  T. Duhamel,et al.  The regulation of sarco(endo)plasmic reticulum calcium-ATPases (SERCA). , 2015, Canadian journal of physiology and pharmacology.

[58]  J. Lau,et al.  CART in the regulation of appetite and energy homeostasis , 2014, Front. Neurosci..

[59]  G. Bruno,et al.  Natriuretic Peptides, Heart, and Adipose Tissue: New Findings and Future Developments for Diabetes Research , 2014, Diabetes Care.

[60]  F. López‐Soriano,et al.  Cancer cachexia: understanding the molecular basis , 2014, Nature Reviews Cancer.

[61]  E. Wagner,et al.  A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. , 2014, Cell metabolism.

[62]  F. López‐Soriano,et al.  Cachexia: a problem of energetic inefficiency , 2014, Journal of cachexia, sarcopenia and muscle.

[63]  F. Villarroya,et al.  Browning of White Adipose Cells by Intermediate Metabolites: An Adaptive Mechanism to Alleviate Redox Pressure , 2014, Diabetes.

[64]  V. Barrios,et al.  Peptides and Food Intake , 2014, Front. Endocrinol..

[65]  A. D. de Bold,et al.  The heart as an endocrine organ , 2014, Endocrine connections.

[66]  T. Guise,et al.  Molecular Mechanisms of Bone Metastasis and Associated Muscle Weakness , 2014, Clinical Cancer Research.

[67]  C. Buettner,et al.  Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism. , 2014, Endocrinology and metabolism clinics of North America.

[68]  Kassem M. Makki,et al.  Adipose Tissue in Obesity-Related Inflammation and Insulin Resistance: Cells, Cytokines, and Chemokines , 2013, ISRN inflammation.

[69]  Audrey L. Shaw,et al.  Gut barrier dysfunction and microbial translocation in cancer cachexia: a new therapeutic target , 2013, Current opinion in supportive and palliative care.

[70]  N. Delzenne,et al.  Muscle wasting: the gut microbiota as a new therapeutic target? , 2013, The international journal of biochemistry & cell biology.

[71]  M. Matsuura.  Structural Modifications of Bacterial Lipopolysaccharide that Facilitate Gram-Negative Bacteria Evasion of Host Innate Immunity , 2013, Front. Immunol..

[72]  S. Kuang,et al.  Myostatin knockout drives browning of white adipose tissue through activating the AMPK‐PGC1α‐Fndc5 pathway in muscle , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[73]  J. Moreno-Navarrete,et al.  Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. , 2013, The Journal of clinical endocrinology and metabolism.

[74]  W. Cheung,et al.  Melanocortin antagonism ameliorates muscle wasting and inflammation in chronic kidney disease. , 2012, American journal of physiology. Renal physiology.

[75]  P. Martínez-Hernández,et al.  Serum interleukin-15 levels in cancer patients with cachexia. , 2012, Oncology reports.

[76]  S. Clarke,et al.  Activation of thermogenesis in brown adipose tissue and dysregulated lipid metabolism associated with cancer cachexia in mice. , 2012, Cancer research.

[77]  S. Anker,et al.  Theophylline is able to partially revert cachexia in tumour-bearing rats , 2012, Nutrition & Metabolism.

[78]  S. Gygi,et al.  Ubiquitylation by Trim32 causes coupled loss of desmin, Z-bands, and thin filaments in muscle atrophy , 2012, The Journal of cell biology.

[79]  D. McMillan,et al.  The Relationships between Body Composition and the Systemic Inflammatory Response in Patients with Primary Operable Colorectal Cancer , 2012, PloS one.

[80]  M. Deyoung,et al.  GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence , 2012, Diabetes, obesity & metabolism.

[81]  T. Zimmers,et al.  JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. , 2012, American journal of physiology. Endocrinology and metabolism.

[82]  F. López‐Soriano,et al.  Myostatin: more than just a regulator of muscle mass. , 2012, Drug discovery today.

[83]  J. Verrax,et al.  Restoring Specific Lactobacilli Levels Decreases Inflammation and Muscle Atrophy Markers in an Acute Leukemia Mouse Model , 2012, PloS one.

[84]  P. Fayers,et al.  Is there a genetic cause of appetite loss?—an explorative study in 1,853 cancer patients , 2012, Journal of cachexia, sarcopenia and muscle.

[85]  M. Febbraio,et al.  Muscles, exercise and obesity: skeletal muscle as a secretory organ , 2012, Nature Reviews Endocrinology.

[86]  T. Motyl,et al.  A role of ghrelin in cancerogenesis. , 2012, Polish journal of veterinary sciences.

[87]  B. Spiegelman,et al.  A PGC1α-dependent myokine that drives browning of white fat and thermogenesis , 2012, Nature.

[88]  Tiewen Liu,et al.  Hypothalamic inflammation: a double‐edged sword to nutritional diseases , 2011, Annals of the New York Academy of Sciences.

[89]  J. Baynes,et al.  Gut barrier dysfunction in the Apc(Min/+) mouse model of colon cancer cachexia. , 2011, Biochimica et biophysica acta.

[90]  Y. Nishijima,et al.  Evidence for cardiac atrophic remodeling in cancer-induced cachexia in mice. , 2011, International journal of oncology.

[91]  I. Reid,et al.  Ghrelin is an Osteoblast Mitogen and Increases Osteoclastic Bone Resorption In Vitro , 2011, International journal of peptides.

[92]  Nathalie M. Delzenne,et al.  Targeting gut microbiota in obesity: effects of prebiotics and probiotics , 2011, Nature Reviews Endocrinology.

[93]  C. Diwoky,et al.  Adipose Triglyceride Lipase Contributes to Cancer-Associated Cachexia , 2011, Science.

[94]  J. Ross,et al.  Intramyocellular lipid droplets increase with progression of cachexia in cancer patients , 2011, Journal of cachexia, sarcopenia and muscle.

[95]  W. Kummer,et al.  Cancer Induces Cardiomyocyte Remodeling and Hypoinnervation in the Left Ventricle of the Mouse Heart , 2011, PloS one.

[96]  S. Kügler,et al.  Proliferative Hypothalamic Neurospheres Express NPY, AGRP, POMC, CART and Orexin-A and Differentiate to Functional Neurons , 2011, PloS one.

[97]  Paula Ravasco,et al.  Definition and classification of cancer cachexia: an international consensus. , 2011, The Lancet. Oncology.

[98]  T. Ziegler,et al.  Nutritional interventions for cancer-induced cachexia. , 2011, Current problems in cancer.

[99]  D. Talwar,et al.  An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study , 2011, British Journal of Cancer.

[100]  P. Arner,et al.  Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients , 2011, British Journal of Cancer.

[101]  J. Hopkinson.  The emotional aspects of cancer anorexia , 2010, Current opinion in supportive and palliative care.

[102]  A. Molfino,et al.  Contribution of anorexia to tissue wasting in cachexia , 2010, Current opinion in supportive and palliative care.

[103]  B. Aggarwal,et al.  Oxidative stress, inflammation, and cancer: how are they linked? , 2010, Free radical biology & medicine.

[104]  D. Lacey,et al.  Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival , 2010, Cell.

[105]  Y. Nishijima,et al.  Cardiac alterations in cancer-induced cachexia in mice. , 2010, International journal of oncology.

[106]  D. Marks,et al.  Hypothalamic mechanisms in cachexia , 2010, Physiology & Behavior.

[107]  C. Bing,et al.  Zinc-α2-glycoprotein: an adipokine modulator of body fat mass? , 2010, International Journal of Obesity.

[108]  K. Clément,et al.  Adipose tissue pathways involved in weight loss of cancer cachexia , 2010, British Journal of Cancer.

[109]  M. Tisdale.  Are tumoral factors responsible for host tissue wasting in cancer cachexia? , 2010, Future oncology.

[110]  T. Nemoto,et al.  Genetic suppression of ghrelin receptors activates brown adipocyte function and decreases fat storage in rats , 2010, Regulatory Peptides.

[111]  R. Datta,et al.  Ghrelin in the regulation of body weight and metabolism , 2010, Frontiers in Neuroendocrinology.

[112]  D. Kufe,et al.  Mucins in cancer: function, prognosis and therapy , 2009, Nature Reviews Cancer.

[113]  E. Karapanagiotou,et al.  Increased serum levels of ghrelin at diagnosis mediate body weight loss in non-small cell lung cancer (NSCLC) patients. , 2009, Lung cancer.

[114]  R. Ritchie,et al.  B-type natriuretic peptide: endogenous regulator of myocardial structure, biomarker and therapeutic target. , 2009, Current molecular medicine.

[115]  G. Wakabayashi,et al.  Ghrelin and leptin levels in cachectic patients with cancer of the digestive organs , 2009, International Journal of Clinical Oncology.

[116]  C. Mammucari,et al.  Smad2 and 3 transcription factors control muscle mass in adulthood. , 2009, American journal of physiology. Cell physiology.

[117]  M. Terashima,et al.  Expression of tight-junction-associated proteins in human gastric cancer: downregulation of claudin-4 correlates with tumor aggressiveness and survival , 2009, Gastric Cancer.

[118]  Xiaoying Yin,et al.  NF‐¿B inhibition protects against tumor‐induced cardiac atrophy in vivo , 2009, The American journal of pathology.

[119]  W. Mitch,et al.  IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. , 2009, Journal of the American Society of Nephrology : JASN.

[120]  F. López‐Soriano,et al.  Therapeutic potential of interleukin-15: a myokine involved in muscle wasting and adiposity. , 2009, Drug discovery today.

[121]  P. Ponikowski,et al.  Cachexia: a new definition. , 2008, Clinical nutrition.

[122]  A. Bedirli,et al.  Adipokines and ghrelin in gastric cancer cachexia. , 2008, World journal of gastroenterology.

[123]  F. Cavagnini,et al.  Neuroendocrine control of food intake. , 2008, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[124]  F. López‐Soriano,et al.  Mechanisms to explain wasting of muscle and fat in cancer cachexia , 2007, Current opinion in supportive and palliative care.

[125]  L. Tecott.  Serotonin and the orchestration of energy balance. , 2007, Cell metabolism.

[126]  D. Lenihan,et al.  Cancer Patients With Markedly Elevated B-Type Natriuretic Peptide May Not Have Volume Overload , 2007, American journal of clinical oncology.

[127]  M. Granado,et al.  Experimental arthritis inhibits the insulin-like growth factor-I axis and induces muscle wasting through cyclooxygenase-2 activation. , 2007, American journal of physiology. Endocrinology and metabolism.

[128]  J. Pisegna,et al.  Elevated Serum Ghrelin Exerts an Orexigenic Effect that May Maintain Body Mass Index in Patients with Metastatic Neuroendocrine Tumors , 2007, Journal of Molecular Neuroscience.

[129]  M. Joppa,et al.  Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83-132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice , 2007, Peptides.

[130]  Jeffrey I. Gordon,et al.  Mechanisms underlying the resistance to diet-induced obesity in germ-free mice , 2007, Proceedings of the National Academy of Sciences.

[131]  Jiandie D. Lin,et al.  PGC-1α protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription , 2006, Proceedings of the National Academy of Sciences.

[132]  R. Skipworth,et al.  Cancer cachexia and fatigue. , 2006, Clinical medicine.

[133]  J. Auwerx,et al.  Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation , 2006, Nature.

[134]  P. Costelli,et al.  Ca(2+)-dependent proteolysis in muscle wasting. , 2005, The international journal of biochemistry & cell biology.

[135]  C. Peterson,et al.  Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. , 2005, Diabetes.

[136]  V. Almendro,et al.  Cross‐talk between skeletal muscle and adipose tissue: A link with obesity? , 2005, Medicinal research reviews.

[137]  Ki-Choon Choi,et al.  The role of ghrelin and growth hormone secretagogues receptor on rat adipogenesis. , 2003, Endocrinology.

[138]  Andrew J S Coats,et al.  Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. , 2003, Journal of cardiac failure.

[139]  A. Asakawa,et al.  Anticancer drugs that induce cancer-associated cachectic syndromes , 2002, Expert review of anticancer therapy.

[140]  M. Nakazato,et al.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach , 1999, Nature.

[141]  R. Miller,et al.  Increased tight junctional permeability is associated with the development of colon cancer. , 1999, Carcinogenesis.

[142]  F. López‐Soriano,et al.  The metabolic basis of cancer cachexia , 1997, Medicinal research reviews.

[143]  J. Gelin,et al.  Acute-phase proteins in response to tumor growth. , 1993, The Journal of surgical research.

[144]  K. Lundholm,et al.  Glucose uptake and amino acid metabolism in perfused hearts from tumor-bearing rats. , 1990, The Journal of surgical research.

[145]  J. Pfeilschifter,et al.  Atrial natriuretic peptide inhibits renin release from juxtaglomerular cells by a cGMP-mediated process. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[146]  R. Makuch,et al.  Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer. , 1985, Cancer research.

[147]  Joseph R. Bertino,et al.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. , 1980, The American journal of medicine.

[148]  S. Warren.  THE IMMEDIATE CAUSES OF DEATH IN CANCER , 1932 .

[149]  F. Villarroya,et al.  Adipokines and the Endocrine Role of Adipose Tissues. , 2016, Handbook of experimental pharmacology.

[150]  P. Delafontaine,et al.  THE RENIN-ANGIOTENSIN SYSTEM AND THE BIOLOGY OF SKELETAL MUSCLE: MECHANISMS OF MUSCLE WASTING IN CHRONIC DISEASE STATES. , 2016, Transactions of the American Clinical and Climatological Association.

[151]  B. Spiegelman,et al.  Forum Cachexia and Brown Fat : A Burning Issue in Cancer , 2016 .

[152]  S. Bodine,et al.  Glucocorticoids and Skeletal Muscle. , 2015, Advances in experimental medicine and biology.

[153]  Y. Siow,et al.  The CBS/CSE system: a potential therapeutic target in NAFLD? , 2015, Canadian journal of physiology and pharmacology.

[154]  S. B. Peres,et al.  Adipose tissue inflammation and cancer cachexia: possible role of nuclear transcription factors. , 2012, Cytokine.

[155]  F. López‐Soriano,et al.  Counteracting inflammation: a promising therapy in cachexia. , 2012, Critical reviews in oncogenesis.

[156]  M. Ruth.  A PGC1–α–dependent myokine that drives brown–fat–like development of white fat and thermogenesis , 2012 .

[157]  Vidhi Gautam,et al.  Acute-phase proteins: As diagnostic tool , 2011, Journal of pharmacy & bioallied sciences.

[158]  D. McMillan,et al.  Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. , 2010, Future oncology.

[159]  J. Argilés,et al.  Oversecretion of interleukin-15 from skeletal muscle reduces adiposity. , 2009, American journal of physiology. Endocrinology and metabolism.

[160]  H. Friess,et al.  Liver macrophages contribute to pancreatic cancer-related cachexia. , 2009, Oncology reports.

[161]  K. Lundholm,et al.  Elevated energy expenditure in cancer patients with solid tumours. , 1991, European journal of cancer.

[162]  D. Gandara,et al.  Progress in the control of acute and delayed emesis induced by cisplatin. , 1991, European journal of cancer.

[163]  J. Ambrus,et al.  Causes of death in cancer patients. , 1975, Journal of medicine.

[164]  L. Leinwand,et al.  Molecular and Cellular Pathobiology Cancer Causes Cardiac Atrophy and Autophagy in a Sexually Dimorphic Manner , 2011 .